moatshark My

All holdings

Abbott Laboratories

ABT

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding
8
In their latest 13F (Q3 2026)
See who
Value held
$232m
Combined value at quarter end
Last quarter
4 bought
2 sold or trimmed
Fund portfolios
2
Funds holding it
See which
Price at Q3 ’26 end
$98.83
+8.9% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

-0.8%Q4 ’24
+17.3%Q1 ’25
+2.5%Q2 ’25
-1.5%Q3 ’25
-6.5%Q4 ’25
-18.1%Q1 ’26
-11.6%Q2 ’26
+8.9%Q3 ’26
Q4 ’24: -0.8%; Q1 ’25: +17.3%; Q2 ’25: +2.5%; Q3 ’25: -1.5%; Q4 ’25: -6.5%; Q1 ’26: -18.1%; Q2 ’26: -11.6%; Q3 ’26: +8.9%

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

7Q4 ’23
7Q1 ’24
7Q2 ’24
7Q3 ’24
7Q4 ’24
6Q1 ’25
7Q2 ’25
7Q3 ’25
7Q4 ’25
6Q1 ’26
8Q2 ’26
1Q3 ’26
Q4 ’23: 7; Q1 ’24: 7; Q2 ’24: 7; Q3 ’24: 7; Q4 ’24: 7; Q1 ’25: 6; Q2 ’25: 7; Q3 ’25: 7; Q4 ’25: 7; Q1 ’26: 6; Q2 ’26: 8; Q3 ’26: 1

Counts the managers on this site whose 13F for that quarter includes Abbott Laboratories.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Abbott Laboratories
Southeastern Asset Management4.0%$76.3m$76.3mNew1 qtr
Jensen Investment Management1.9%$80.3m$80.3mTrimmed -40%53 qtrs
Mairs & Power0.6%$66.2m$66.2mAdded +1.1%53 qtrs
Matrix Asset Advisors0.4%$5.2m$5.2mAdded +12%2 qtrs
Gardner Russo & Quinn0.0%$1.0m$1.0mUnchanged53 qtrs
Horizon Kinetics0.0%$882k$882kAdded +1.6%30 qtrs
Dodge & Cox0.0%$1.6m$1.6mUnchanged53 qtrs
Polen Capital Management0.0%$286k$286kTrimmed -79%28 qtrs

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works
From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.
Insider purchases and sales of Abbott Laboratories
Bought or soldFiling
2 Sep 2026Mccoy John A. Jr.VICE PRESIDENT AND CONTROLLER▼ Sold27$109.54$3kForm 4
25 Aug 2026Ford Robert BCHAIRMAN AND CEO▼ Sold218,535$115.57$25.3mForm 4
25 Aug 2026Ford Robert BCHAIRMAN AND CEO▼ Sold180,297$116.19$20.9mForm 4
11 Aug 2026Morrone Louis H.EXECUTIVE VICE PRESIDENT▼ Sold5,850$109.83$643kForm 4

About the company

Sector
Health care · Pharmaceutical Preparations
Incorporated in
Illinois
Financial year ends
31 December
Shares outstanding
1.73bn at 30 Jun 2026
SEC filings
Annual reports and other filings on EDGAR

Revenue and profit

$20bn2013
$20bn2015
$27bn2017
$32bn2019
$43bn2021
$40bn2023
$44bn2025
2013: $20bn; 2014: $20bn; 2015: $20bn; 2016: $21bn; 2017: $27bn; 2018: $31bn; 2019: $32bn; 2020: $35bn; 2021: $43bn; 2022: $44bn; 2023: $40bn; 2024: $42bn; 2025: $44bn
Abbott Laboratories revenue and net income by year
YearRevenueNet income
2025$44bn$6.5bn
2024$42bn$13bn
2023$40bn$5.7bn
2022$44bn$6.9bn
2021$43bn$7.1bn
2020$35bn$4.5bn
2019$32bn$3.7bn
2018$31bn$2.4bn
2017$27bn$477m
2016$21bn$1.4bn
2015$20bn$4.4bn
2014$20bn$2.3bn
2013$20bn$2.6bn

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.

In fund portfolios

US-registered funds run by these managers that hold Abbott Laboratories, from their latest N-PORT filings.

Funds holding Abbott Laboratories
Longleaf Partners Global FundSoutheastern Asset Management3.2%$22.1m30 Jun 2026
Jensen Quality Growth FundJensen Investment Management1.8%$53.1m31 May 2026